In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emerging Markets Earnings Roundup: Roche, Lilly, Bristol Myers Squibb (Part 2)

This article was originally published in PharmAsia News

Executive Summary

China remains the star in emerging markets, with Roche reporting 26% growth in China for pharma and 19% in diagnostics, and Eli Lilly & Co. reporting 18% growth in China. Bristol-Myers Squibb Co. had little to report on EMs, but it signed a manufacturing agreement with South Korea’s Samsung BioLogics for an undisclosed cancer drug.

You may also be interested in...



Earnings Briefs: Actavis, Celgene, InterMune, Lilly, Forest

Companies are reporting out their half-year earnings and giving investors updates on the progress of their pipelines, as well as ongoing launch plans. Actavis and Warner Chilcott are in line as their merger approaches; Lilly’s Lechleiter gives an update on BD plans; AbbVie talks about its HCV combo; and Shire recommits to ADHD promotion.

Roche Follow-On Development Strategy Highlighted By Strong 1H Results

Top oncology specialist Roche’s second quarter saw robust sales growth with new breast cancer medicines Perjeta and Kadcyla selling well, highlighting and further validating its strategy to develop follow-on drugs to replace or renew older treatments while expanding into new disease areas.

List Ahead For Southeast Asia Pharma In 2015

PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.

Topics

Related Companies

UsernamePublicRestriction

Register

SC085005

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel